PanGenex (PGXC) Introduces LIPIDEME™ to
Lower Cholesterol Naturally and Increase Cardiovascular Health
TAMPA, Fla. (Business Wire EON/PRWEB ) June 8, 2008 --
PanGenex Corporation (Pink Sheets: PGXC) announces the product launch of
LIPIDEME™, an all-natural nutraceutical
formulated with scientifically proven ingredients and the first product
on the market to combine the triglyceride-lowering power of Omega-3
fatty acids with the cholesterol lowering ability of phytosterols and
tocotrienols – plus the free-radical fighting
capacity of Coenzyme Q10 (CoQ10).
Dr. Eric J. Springer, Chiropractic Physician with Northeast Chiropractic
states that “LIPIDEME is one of the most
exciting products out there today. LIPIDEME is an easy and effective way
to help reduce cholesterol and improve cardiovascular health. As a
Physician I look for the highest quality when recommending products to
my patients. I’ve experienced the results of
LIPIDEME personally and they speak for themselves. LIPIDEME is the gold
standard in natural cholesterol lowering supplements.”
LIPIDEME is formulated with pharmaceutical grade fish oil that is over
86% pure Omega-3s; the highest content available without a prescription
for heart, mental, joint and skin health. The Omega-3s in LIPIDEME are
molecularly distilled and tested to ensure that there are no detectable
levels of Mercury, PCBs, or other toxins or heavy metals. The US Food
and Drug Administration and the American Heart Association all recommend
the consumption of Omega-3 fatty acids from fish, and state that
Omega-3s provide much needed protection for your heart.
LIPIDEME provides the proper amount of phytosterols to assist in
naturally lowering the amount of cholesterol that is absorbed through
food. Phytosterols are natural, plant derived compounds that when
taken in appropriate amounts, block the absorption of cholesterol from
food. Phytosterol administration has been proven to result in lower
serum levels of bad cholesterol (LDL), yet show no reduction in good
cholesterol, (HDL).
LIPIDEME contains tocotrienols, part of the vitamin E family, which are
a 40-60 time more potent antioxidant than the common form of vitamin E,
tocopherol. Research shows that delta and gamma tocotrienols inhibit
cholesterol production in the liver. Tocotrienols do not effect liver
health or rob the body of CoQ10.
LIPIDEME in formulated with CoQ10 which has been the subject of
thousands of clinical trials and has been shown to be a potent
antioxidant and to boost energy, especially in cardiac muscle tissue.
LIPIDEME can be purchased through the Internet at www.PanGenex.com.
LIPIDEME is also commercially available through qualified practitioners
across the country with new practitioners ordering the product daily.
PanGenex anticipates practitioners, distributors and retail sales to
increase as LIPIDEME is launched throughout the country.
(1) The statements in this press release have
not been evaluated by the Food and Drug Administration. This product is
not intended to diagnose, treat, cure or prevent any disease.
Learn More about Dr. Eric Springer at:
www.northeastchiropractor.com
About PanGenex Corporation:
PanGenex is a publicly traded corporation (PINK SHEETS: PGXC) and
pursues business opportunities in the $60 billion dollar nutraceutical
and dietary supplement industry. With a focus specifically on the
cardiovascular health segment, PanGenex develops and markets sector
leading, patented or patent pending, condition specific nutraceuticals
and topical over-the-counter (OTC) drugs and personal care products.
Each product is scientifically formulated to address specific health
conditions throughout the population. Many of our products contain the
purest grade of nutraceutical components available anywhere without a
prescription. PanGenex markets products through healthcare practitioners
throughout the U.S., fine retail establishments and the internet on
websites such as www.PanGenex.com
and www.Calgenex.com.
Disclaimer:
CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements," which are
statements related to future, not past, events. In this context, the
forward-looking statements often include statements regarding our goals,
plans, projections and guidance regarding our financial position,
results of operations, market position, pending and potential future
acquisitions and business strategy, and often contain words such as
"expects," "anticipates," "intends," "plans," "believes," "seeks" or
"will." Any such forward-looking statements are not assurances of future
performance and involve risks and uncertainties that may cause results
to differ materially from those set forth in the statements. These risks
and uncertainties include, among other things, (a) general economic and
business conditions, (b) the level of strategic partner incentives, (c)
the future regulatory environment, (d) our cost of financing, (e) our
ability to complete acquisitions and dispositions and the risks
associated therewith, and (f) our ability to retain key personnel. These
factors, as well as additional factors, could affect our forward-looking
statements. We urge you to carefully consider this information. We
undertake no duty to update our forward-looking statements, including
our earnings outlook.
See the original story at: http://eon.businesswire.com/releases/lipideme/pangenex/prweb1008854.htm
Post Comment: Trackback URL: http://www.prweb.com/pingpr.php/SW5zZS1GYWx1LVNxdWEtSW5zZS1Qcm9mLVplcm8=
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|